Navigation Links
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
Date:12/9/2008

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. Dr. Sherif Farag, Associate Professor, Department of Medicine, will serve as principal investigator.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Primary objectives for the dose escalation study include determining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 when administered orally once a day in patients with multiple myeloma who are refractory to other drug therapy. The study will also assess the safety, tolerability, pharmacodynamic effects and activity of ENMD-2076 in this patient population.

Preclinical data supporting the clinical evaluation of ENMD-2076 alone and in combination in multiple myeloma were presented by Dr. Farag earlier this week at the American Society of Hematology Annual Meeting in San Francisco, CA. ENMD-2076 was shown to induce rapid apoptosis (cell death) in multiple myeloma cell lines in vitro. Significant dose-dependent antitumor activity with minimal toxicity was also induced in vivo when ENMD-2076 was administered as a single agent in multiple myeloma models. Combination studies with ENMD-2076 and lenalidomide (Revlimid(R)) in vitro indicated synergistic cytotoxic activity towards several human multiple myeloma cell lines. ENMD-2076 was shown, both in vitro and in vivo, to have minimal toxicity towards human and murine h
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2009)...e-FirstCall/ -- Gerresheimer AG, a,leading manu­...rma & life,science industry, has sold its Tec... the MDAX company,s core business, to the FBH Grou...echnical Plastics segment Gerresheimer has,- as f...cus on the core,business of pharma & life sci...
(Date:6/30/2009)... HONG KONG, June 30 EFT ...ced today that Excalibur,s Ocean LaLa has successf...er voyage which has been highlighted in multiple n...e Taiwan Sun, and the Qatar Tribune. The article ...e service with China on Sunday, making it the firs...
(Date:6/30/2009)...all/ -- In connection with its proposed acquisitio...Concateno plc, announced on June 5 2009, Inverness... requested by the UK Takeover Panel to remind Inve...eir dealing disclosure obligations under Rule 8.3 ...e requirements of the UK Takeover Code , , Und...
(Date:6/30/2009)...all/ -- Novavax, Inc. (Nasdaq: NVAX ) announced ...tary, recombinant virus-like-particle (VLP) vaccin...) of Spain. ROVI will use the VLP technology to c...or the Spanish government under a new 60 million-e...try of Health and other government groups to devel...
Breaking Biology Technology:Gerresheimer Sells Technical Plastics Business 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 3Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements. 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 3Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 4Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 5
...Milwaukee, Wis. - Wisconsin can create a dynamic,...lly cutting taxes and shedding its "welfare state"...a gathering of business executives. , ,John Jazwie...iticized the state,s business climate, outlined wh... Economic Trends Breakfast of the Independent Bus...
...Madison, Wis. - Almost everybody knows the Unive...conomy by generating high-tech spin-off companies.... assertion. , ,Many of the 114 companies housed in...es west of campus, are developing products based o...ese innovative firms, according to the study, has ...
...Waukesha, Wis. - Fairview Hospital in Cleveland...GE Healthcare technology that, when combined with...etricians to remotely monitor the real-time condit...from its labor and delivery units. , ,The informat...a, maternal contraction patterns, and electronic f...
...Madison, Wis. - Gov. Jim Doyle is urging the W...mark for biomedical research in southeastern Wisco...ach the funds to his proposed 2007-09 executive bu...e , a group of investors and researchers from sout...d match the funds, creating a $5 million sum to fo...
Other Biology Technology:RedPrairie exec calls for 50 percent tax cut 2RedPrairie exec calls for 50 percent tax cut 3RedPrairie exec calls for 50 percent tax cut 4Impact of research park firms pegged at $680M 2GE partner allows real-time access to patient data 2Doyle seeks $2.5M for biomedical alliance 2
(Date:7/2/2009)...rs from the National Oceanography Centre, Southamp...ographic knowledge to investigate the distribution...e results, published this week in the Journal of ...ce behind the speciation and radiation of a major ...ions of years of Earth,s history. , In deep sea...
(Date:7/2/2009)...h, Ph.D., an assistant professor of pathology and ...lth Science Center at Houston, has received a Care...Foundation. , The award will support Smith,s re...e with Hemophilia A, a bleeding disorder, whose im...a A affects about one in every 5,000 males born in...
(Date:7/2/2009)...s have performed the first DNA-based reconstructio... feathers recovered from caves and rock shelters i... of Adelaide and Landcare Research in New Zealand ...etrieving ancient DNA from moa feathers believed t... measuring up to 2.5 metres and weighing 250 kilog...
(Date:7/1/2009)...rsity of Manchester and the European Molecular Bio...e (EMBL-EBI) have launched a major new e-science r...earch into treatments for H1N1 flu and cancer. , ...ated life science Web Services, is being officiall...nual International Conference on Intelligent Syste...
Breaking Biology News(10 mins):Evolution: Crabs go deep to avoid hot water 2UT scientist receives hemophilia research award 2Scientists 'rebuild' giant moa using ancient DNA 2New e-science service could accelerate cancer research 2Bullying Prevention Institute Designed to Empower Change in Schools 2498 1Bullying Prevention Institute Designed to Empower Change in Schools 2498 2Bullying Prevention Institute Designed to Empower Change in Schools 2498 3Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3 36 Nasal Spray to Treat Obesity 416 1Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3 36 Nasal Spray to Treat Obesity 416 2Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3 36 Nasal Spray to Treat Obesity 416 3Progress Against Malaria 3A Developments on the Horizon 623 1Progress Against Malaria 3A Developments on the Horizon 623 2Three way mating game of North American lizard found in distant European relative 621 1Three way mating game of North American lizard found in distant European relative 621 2Three way mating game of North American lizard found in distant European relative 621 3Three way mating game of North American lizard found in distant European relative 621 4
...rologists have discovered that a specific human pr...uman genome. Their findings show that when HIV ins...bles it to establish a "safe haven," it requires a... forms a molecular tether between chromosomes and ...ection can be disrupted in the future, it might le...
...ogs and using the latest in imaging software and m...ns Hopkins heart specialists have developed a fast...n slowed down by narrowing of the coronary arterie...e time of exercise stress tests and echocardiogra... more likely to become blocked and cause heart att...
...ug approach, researchers at Children,s Hospital Bo...rescue heart function after a heart attack and pro...hey combined an agent that overcomes a natural inh... growth factor that encourages blood vessel growth...d heart-muscle cells to multiply and the heart to ...
... the Salk Institute for Biological Studies in coll...ifornia, San Diego (UCSD) took a high resolution "...ial role in the development of the nervous system....the journal Molecular Cell, provide a template for...l that switch, a protein called Scp1, at will. , "...
Other Biology News:Mayo researchers discover HIV dependence on a human protein 2Fast test for low blood flow in dogs detects early heart trouble 2Fast test for low blood flow in dogs detects early heart trouble 3Fast test for low blood flow in dogs detects early heart trouble 4Rescuing injured hearts by enhancing regeneration 2Rescuing injured hearts by enhancing regeneration 3Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3
Polyethylene Glycol 8000, 1 kg. PEG 8000.Used in differential DNA precipitation. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals .
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary Alexa Fluor dyes and they are useful for assessing microarray spot morphology, hybridization pot
Mycoplasma tested
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast
Biology Products: